Immunic, Inc.
IMUX
$12.31
$0.120.98%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 23.49% | 78.70% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.29% | 42.47% | |||
| Operating Income | -6.29% | -42.47% | |||
| Income Before Tax | -4.64% | -68.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.64% | -68.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.64% | -68.85% | |||
| EBIT | -6.29% | -42.47% | |||
| EBITDA | -6.30% | -42.59% | |||
| EPS Basic | 25.83% | -8.88% | |||
| Normalized Basic EPS | 25.82% | -19.38% | |||
| EPS Diluted | 25.83% | -8.88% | |||
| Normalized Diluted EPS | 25.82% | -19.38% | |||
| Average Basic Shares Outstanding | 41.07% | 55.09% | |||
| Average Diluted Shares Outstanding | 41.07% | 55.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||